SPpPU and TUHH Scientists creates closed-loop technology from microalgae

QS WOWNEWS | July 18, 2020

Researchers of Peter the Great St. Petersburg Polytechnic University (SPbPU) in collaboration with Hamburg University of Technology (TUHH) completed an international joint project to create a resource and CO2-neutral energy closed-loop technology from microalgae Chlorella sorokiniana and duckweed Lemna minor. According to Professor  Kerstin Kuchta, Vice president of TUHH and the project coordinator from the German side, the main objective of the project was development and implementation of an innovative approach for microalgae and duckweed bio-refinery to produce valuable products with further utilization of residual biomass for wastewater treatment and energy generation. “In the process of project implementation, several technological solutions were developed and patented: obtaining lipids for biofuels, obtaining pectin and pigments for nutrition purposes, obtaining sorbents for water purification, as well as obtaining biogas from algae waste to generate energy,” said Natalia Politaeva, the professor of  Higher School of Hydrotechnical and Power Engineering SPbPU, and the project supervisor from the Russian side.

Spotlight

Developing these relationships among all these parties is vital for advancing drug discovery and development–because Patients can’t wait. And that’s why we are so pleased to present this white paper–Patient Advocacy: An emerging role within pharma and biotechnology.


Other News
CELL AND GENE THERAPY

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS Biotech. An inducement grant of 20,000 shares of PDS Biotech’s common stock, in accordance with Nasdaq Listing Rule 5635(c)(4), was awarded as part of Mr. Lalond’s compensation. The award was granted under PDS Biotech’s 2019 Inducement Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4) and provides for the granting of equity awards to new employees of PDS Biotech. The option award has an exercise price of $8.87, the closing price of PDS Biotech’s common stock on December 20, 2021. About PDS Biotechnology PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.

Read More

INDUSTRIAL IMPACT

Canopy Biosciences Launches Next-Generation ChipCytometry™ Instrument for Spatial Biology with Sub-Cellular Resolution

Canopy Biosciences | March 04, 2022

Canopy Biosciences, a Bruker Company, announced the commercial launch of the CellScapeTM system, the next generation in ChipCytometryTM instrumentation, advancing the cutting-edge for quantitative in situ spatial phenotyping. ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumor microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease. The new benchtop CellScape system builds on the existing core strengths of the original ChipCytometry instrument, the ZellScannerONE™, which has enabled spatial biology research with sub-cellular resolution and a large field of view suitable for whole slide pathology imaging, on both tissue samples and cell suspensions since 2016. The CellScape system , with its multiplexed fluidics integration, adds complete walk-away automation, improved optical performance, sub-cellular resolution and massively increased throughput for whole slide imaging of millions of cells, while maintaining the key features of the core ChipCytometry technology, including high-plex phenotyping with single-cell resolution, very high dynamic range imaging for detection and quantification of both high- and low-expressing targets, and compatibility with standard commercially available fluorescently labelled antibodies, requiring no proprietary antibody conjugation. This powerful combination of features will significantly improve researchers’ workflow, accelerate spatial biology discovery, and drive broader adoption of high-plex spatial omics for translational and clinical applications. “The ChipCytometry platform has been a great tool for us in developing high content staining approaches for in-depth spatial immune profiling of human tissue samples. The improvements to throughput and automation of the CellScape system gives the opportunity to scale up studies and explore larger cohorts – and accelerate studies aimed at improving patient care.” Paul Klenerman, Ph.D., Professor of Gastroenterology at The University of Oxford “Following the acquisition of Canopy Biosciences by Bruker in 2020, we were able to leverage Bruker’s advanced fluorescence microscopy expertise to design the CellScape instrument as an integrated, multiplexed imaging system that is highly optimized for the application of high-throughput quantitative spatial omics with sub-cellular resolution,” added Thomas Campbell, Ph.D., Product Manager at Canopy Biosciences. “The improved optical performance of the system builds on the high resolution and high dynamic range that was already best-in-class with our ChipCytometry technology.” About the CellScape Instrument Through enhanced optics and automation, the throughput of CellScape is markedly improved compared to the previous generation of ChipCytometry instrumentation. Combined with multi-sample automated processing, which is available standard with every CellScape, the platform will have among the highest throughput of any highly multiplexed spatial proteomics system available today. CellScape will also be available with an optional FalconFastTM configuration, which provides an even greater increase in throughput, bringing into reach large-scale clinical studies that have previously not been possible at a high plex. About Canopy Biosciences, a Bruker Company Canopy Biosciences was formed in 2016 and rapidly built a comprehensive portfolio of products and services for spatial biology, multi-omics, and bioprocessing. Canopy offers its ChipCytometry technology for precise spatial multiplexing in cells and tissue samples, along with other technologies of ultrasensitive DNA sequencing (RareSeq), RNA-Seq, and gene expression analysis for services. Canopy Biosciences is headquartered in St. Louis, Missouri, with a CLIA site in California, and a site in Germany to serve researchers at universities, research institutions, and biotechnology and pharmaceutical companies worldwide. Canopy was acquired by Bruker Corporation in 2020.

Read More

DIAGNOSTICS

NEOGEN® and Gencove Launch InfiniSEEK™ -- The First Whole Genome and Genotyping Sequencing Solution for Cattle Breeders

NEOGEN | May 16, 2022

NEOGEN® Corporation (NASDAQ: NEOG) and Gencove, the leading low-pass whole genome sequencing and analysis software company, today announced the launch of InfiniSEEK™, an innovative, cost-effective solution for whole genome sequencing and targeted SNP analysis. Combining NEOGEN's world-class genomic solutions and services with Gencove's low-pass sequencing and analytics software, the solution can deliver genomic insights to help advance cattle breeding programs worldwide. NEOGEN offers innovative, high quality, value-added genomic technologies to the agrigenomics industry, With the launch of InfiniSEEK, our customers now have a data-rich, cost-efficient way to get genome-wide sequence data, specific genetic traits, and parentage markers simultaneously with excellent accuracy to characterize cattle across the world. We are excited to add this new solution to NEOGEN's portfolio." Dr. Jason Lilly, NEOGEN's Vice President of International Business. Gencove developed a process that simultaneously yields low-pass whole genome sequencing and high coverage genotyping at pre-selected loci in a single molecular reaction, InfiniSEEK is NEOGEN's first commercial product built on the Gencove software and analysis platform, and we are thrilled it will be deployed through NEOGEN's best in class genomics offering services." Dr. Joseph Pickrell, co-founder and CEO of Gencove. With InfiniSEEK, the industry now has a platform to: Minimize selection bias by sequencing more or all of a population Discover new traits impacting desired phenotypes Reliably manage more than 400 bovine genetic traits and conditions InfiniSEEK has been rigorously validated, and results demonstrate low-pass genome-wide sequencing to be greater than 99 percent concordant to deep whole-genome sequencing and can offer even higher, clinical-grade accuracy at specific regions of interest. About Gencove With additional opportunities to improve human health and the challenge of feeding the world's growing population, demand for genomic information has skyrocketed. To meet the need, Gencove combines low-pass whole genome sequencing (reading the DNA at shallower depths) with a proprietary software-as-a-service computation layer. The result is a high-throughput, cost-effective, accurate sequencing and analysis solution. As evidence of the technology's value, the company has hundreds of customers, and the largest genomics service providers in the world partner with Gencove. About NEOGEN NEOGEN Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "everyday, protect the people and animals we care about." The company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. NEOGEN's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.

Read More

MEDICAL

Genetic Leap and Astellas Establish Research Collaboration to Develop RNA-targeted Small Molecules for Oncology Target

Genetic Leap | March 11, 2022

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discovered and developed under the collaboration that are directed against the program target. Further details of the collaboration were not disclosed. About Genetic Leap Genetic Leap's vision is to lead the next giant leap in human healthcare by developing today the incredible therapeutics of the future. To accomplish this, Genetic Leap built paradigm-shifting AI technologies that find the causal factors in disease and correct these factors with precision RNA therapy that is safe, convenient, and reversible. The company is leveraging its platform to advance a pipeline that spans internal as well as partnered programs, across both novel and known (but traditionally undruggable) targets.

Read More

Spotlight

Developing these relationships among all these parties is vital for advancing drug discovery and development–because Patients can’t wait. And that’s why we are so pleased to present this white paper–Patient Advocacy: An emerging role within pharma and biotechnology.

Resources